Royce Labs seeking court order to allow generic captopril marketing in suit v. Bristol-Myers Squibb.
ROYCE CAPTOPRIL ANDA APPROVAL HINGES ON COURT RULING in a patent infringement suit brought by Capoten innovator Bristol-Myers Squibb. In an Aug. 11 emergency motion filed in response to Bristol's Aug. 4 suit, Royce Labs asks the Miami federal court to order Royce's captopril ANDA effective immediately. The patent suit brought by Bristol under the Waxman/Hatch Act triggers a 30-month stay of approval on the ANDA that can be lifted only by court order.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth